Genotype Distribution Change After Human Papillomavirus Vaccination in Two Autonomous Communities in Spain

Ver/Abrir
Identificadores
URI: http://hdl.handle.net/10902/25081
ISSN: 2235-2988
Compartir
Estadísticas
Ver Estadísticas
Google Scholar
Registro completo
Mostrar el registro completo DC
Autoría
Freire-Salinas, Javier; Benito, Rafael; Azueta Etxebarría, AinaraAutoridad Unican; Gil, Joaquina; Mendoza, Claudia; Nicolás, Montserrat; García-Berbel, Pilar; Algarate, Sonia; Gómez Román, José JavierAutoridad Unican
Fecha
2021
Derechos
Attribution 4.0 International
© The authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Publicado en
Front Cell Infect Microbiol . 2021 Sep 22;11:633162
Editorial
Frontiers Research Foundation
Enlace a la publicación
Palabras clave
Human papillomavirus
Vaccination
Genotype
HPV–infection–prevalence–Europe–risk factors
Change
Resumen/Abstract
Context: It has been more than 10 years since the human papillomavirus (HPV) vaccination program was initiated in most advanced countries. Thus, it seems necessary to change the uterine cervical cancer screening strategy. Molecular-based tests are considered essential in this scenario. Objective: We aimed to review the distribution of the HPV genotypes after the introduction of the vaccination program with Cervarix® and Gardasil 4® in two autonomous communities in Spain, looking for possible changes in distribution and the occurrence of a herd effect. Design: A cross-sectional study was performed in 45,362 samples that were processed in the Cantabria and Aragon communities during the period from 2002 to 2016. We compared the genotype distribution before and after the vaccination program was initiated. Results: Genotypes HPV6 and HPV11 have decreased significantly after the introduction of the vaccine. HPV16 has had a decrease, but not a significant one in the statistical analysis. However, HPV31, HPV52, and HPV45 have increased in percentage. A replacement phenomenon with other genotypes not included in the vaccine has been observed in our population. Conclusions: Continued surveillance is needed to provide further indication of any changes over time in the genotypes in circulation. This will be facilitated by monitoring the genotyping results from the new model of cervical screening using primary HPV DNA testing.
Colecciones a las que pertenece
Attribution 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International